Tag: Pimavanserin

October 31, 2018

ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial

ACADIA Pharmaceuticals (Nasdaq:ACAD) today announced positive top-line results from CLARITY, a randomized, double-blind, placebo-controlled, multi-center, sequential parallel comparison design (SPCD)...
June 29, 2018

ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID (Pimavanserin)

ACADIA Pharmaceuticals (Nasdaq:ACAD) today announced FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID...
December 19, 2016

Tonix Pharmaceuticals’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA

Tonix Pharmaceuticals Holding which is developing a next-generation treatment for PTSD, announced today that the U.S. Food and Drug Administration...
November 15, 2016

ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients

ACADIA Pharmaceuticals, a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today...
October 31, 2016

ACADIA Pharmaceuticals Initiates Phase II Study of Pimavanserin in Alzheimer’s Disease Agitation

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) announced the initiation of SERENE, a Phase II study with pimavanserin for the treatment of...
April 3, 2016

5 Top NASDAQ Biotech Stocks: 5 Companies Gain over 30 Percent Last Week

Gaining over 30 percent for the week were ACADIA Pharmaceuticals, Galena Biopharma, Hasen Medical , Cardiovascular Systems, and Vivus Inc
August 15, 2013

Still Time to Catch Big Growth in Biotech: George Zavoico –

Biotech has had a scorching run for more than a year and a half, but as broader markets approach more...